Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Medecins Sans Frontieres Experience in the Democratic Republic of the Congo

Article Article scientifique Article Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Medecins Sans Frontieres Experience in the Democratic Republic of the Congo fre 2013 author Alirol Emilie 505277 author Schrumpf David 518130 author Amici Heradi J. author Riedel Anette Juliane 76820 author de Patoul C. author Quere M. author Chappuis François 26445 195-203 10.1093/cid/cis886 23074318 1058-4838 Existing diagnostic and treatment tools for human African trypanosomiasis (HAT) are limited. The recent development of nifurtimox-eflornithine combination therapy (NECT) has brought new hopes for patients in the second stage. While NECT has been rolled out in most endemic countries, safety data are scarce and derive only from clinical trials. The World Health Organization (WHO) coordinates a pharmacovigilance program to collect additional data on NECT safety and efficacy. We report here the results of 18 months of experience of NECT use in treatment centers run by Médecins Sans Frontières in the Democratic Republic of the Congo (DRC). Dewey 616 56 Département de médecine 221 false Clinical infectious diseases 56 2 99f97d6b-7b49-44fa-ae2d-808fca0dc8dc Article (Published version) Public Clin Infect Dis.-2013-Alirol-195-203.pdf 194244 application/pdf openAccess Faculté de médecine / Section de médecine clinique / Département de médecine

Title	Published in	Access level	OA Policy	Year	Views	Downloads

Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Medecins Sans Frontieres Experience in the Democratic Republic of the Congo	Clinical infectious diseases			2013	714	539

Archive ouverte UNIGE

Riedel, Anette Juliane